SystImmune doses first patient in Phase III trial for ES-SCLC

SystImmune has dosed the first patient in its global Phase III clinical trial, BrenDeLL-Lung01, assessing BL-M14D1 combined with atezolizumab in those with previously untreated ES-SCLC.

The post SystImmune doses first patient in Phase III trial for ES-SCLC appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.